Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

NCT02013336 is registered in ClinicalTrials.gov with South Plains Oncology Consortium as lead sponsor.

NCT NCT02013336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02013336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Lead sponsor
South Plains Oncology Consortium
Phase
Phase 1
Overall status
Recruiting
Start date
December 31, 2013
Completion date
March 31, 2027
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, neuroblastoma, osteosarcoma, recurrent or refractory solid tumors, rhabdomyosarcoma